U.O.C. Oncologia 2, Istituto Oncologico Veneto I.R.C.C.S.
Welcome,         Profile    Billing    Logout  
 4 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Guarneri, Valentina
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
A-Brave, NCT02926196 / 2016-000189-45: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Hourglass Apr 2021 - Sep 2021 : From A-Brave trial
Active, not recruiting
3
474
Europe
MSB0010718C, Avelumab
Istituto Oncologico Veneto IRCCS, University of Padova, Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche
Triple Negative Breast Neoplasms
06/24
10/25
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting
3
132
Europe
Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
09/29
09/29
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
Neo-AGILE, NCT06259929: NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Recruiting
2
51
Europe
Abemaciclib 150 MG + Giredestrant 30 MG
Fondazione Oncotech
Breast Cancer
04/26
04/27
ATRiBRAVE, NCT05582538: Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Recruiting
2
37
Europe
Ceralasertib, AZD6738, Durvalumab, IMFINZI, Nab-paclitaxel, ABRAXANE, PAZENIR
IFOM ETS - The AIRC Institute of Molecular Oncology, AstraZeneca
Triple Negative Breast Cancer Metastatic
05/25
11/25
KROCUS, NCT05756153: A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting
1/2
45
Europe
GFH925, Cetuximab
Genfleet Therapeutics (Shanghai) Inc.
Advance Non-small Cell Lung Cancer
03/25
08/25
NCT04182516: Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Terminated
1
52
Europe, US, RoW
NMS-03305293
Nerviano Medical Sciences
Advanced/Metastatic Solid Tumors
03/23
05/24
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
METAMECH, NCT04625023: A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer

Recruiting
N/A
500
Europe
Observational
IFOM ETS - The AIRC Institute of Molecular Oncology
Breast Cancer
07/26
12/26
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Guarneri, Valentina
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
A-Brave, NCT02926196 / 2016-000189-45: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Hourglass Apr 2021 - Sep 2021 : From A-Brave trial
Active, not recruiting
3
474
Europe
MSB0010718C, Avelumab
Istituto Oncologico Veneto IRCCS, University of Padova, Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche
Triple Negative Breast Neoplasms
06/24
10/25
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting
3
132
Europe
Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
09/29
09/29
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
Neo-AGILE, NCT06259929: NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Recruiting
2
51
Europe
Abemaciclib 150 MG + Giredestrant 30 MG
Fondazione Oncotech
Breast Cancer
04/26
04/27
ATRiBRAVE, NCT05582538: Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Recruiting
2
37
Europe
Ceralasertib, AZD6738, Durvalumab, IMFINZI, Nab-paclitaxel, ABRAXANE, PAZENIR
IFOM ETS - The AIRC Institute of Molecular Oncology, AstraZeneca
Triple Negative Breast Cancer Metastatic
05/25
11/25
KROCUS, NCT05756153: A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting
1/2
45
Europe
GFH925, Cetuximab
Genfleet Therapeutics (Shanghai) Inc.
Advance Non-small Cell Lung Cancer
03/25
08/25
NCT04182516: Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Terminated
1
52
Europe, US, RoW
NMS-03305293
Nerviano Medical Sciences
Advanced/Metastatic Solid Tumors
03/23
05/24
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
METAMECH, NCT04625023: A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer

Recruiting
N/A
500
Europe
Observational
IFOM ETS - The AIRC Institute of Molecular Oncology
Breast Cancer
07/26
12/26
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26

Download Options